Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

5.160 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amarin Corp ADR

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy 
From GlobeNewswire News Releases
Amarin to Participate in September Investment Conferences
From GlobeNewswire News Releases
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of C
From GlobeNewswire News Releases
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at
From GlobeNewswire News Releases
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiolo
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations 
From GlobeNewswire News Releases
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021
From GlobeNewswire News Releases
Thinking about buying stock in Senseonics, Clean Energy Fuels, Orphazyme, Xpeng, or Amarin Corp?
InvestorsObserver issues critical PriceWatch Alerts for SENS, CLNE, ORPH, XPEV, and AMRN. 
From PR Newswire
Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021
Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in... 
From GlobeNewswire News Releases
Amarin to Present at Two Investor Conferences in June 2021
From GlobeNewswire News Releases
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session
From GlobeNewswire News Releases
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented
From GlobeNewswire News Releases
Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATE 
From GlobeNewswire News Releases
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
From GlobeNewswire News Releases
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
From GlobeNewswire News Releases
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
From GlobeNewswire News Releases
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
From GlobeNewswire News Releases
Amarin Announces CEO Succession Plan
From GlobeNewswire News Releases
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
From GlobeNewswire News Releases
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
From GlobeNewswire News Releases
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care
From GlobeNewswire News Releases
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Con
From GlobeNewswire News Releases
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Amarin to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
From GlobeNewswire News Releases
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
From GlobeNewswire News Releases
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
From GlobeNewswire News Releases
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
From GlobeNewswire News Releases
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.